Another Guy likes AXSM ...more and more people discover this stock and realize the mega potential here https://seekingalpha.com/instablog/...herapeutics-4-biotech-stock-worthy-investment
and another buy rating out today with tgt $14 https://thefly.com/landingPageNews....ome-Therapeutics-initiated-with-a-Buy-at-BTIG Axsome Therapeutics initiated with a Buy at BTIG BTIG analyst Robert Hazlett started coverage of Axsome with a $14 price target and a Buy rating. The analyst says that the company's AXS-05 combination is unique and could treat a number of disorders. He notes that data on the combination's impact on treatment-resistant depression is due in early 2018. Tgh analyst adds that the company's AXS-02 drug "is a novel approach to the treatment of pain," and reports that data on the drug is due out in Q3 and Q4.
Another 1.9 Million shares bought by new institutional investors alone in this month . https://fintel.io/so/us/axsm
Fantastic new director appointed ,, she really must like what she sees at Axsome ... Axsome Therapeutics Appoints Myrtle Potter to its Board of Directors https://finance.yahoo.com/news/axsome-therapeutics-appoints-myrtle-potter-110000754.html Ms. Potter was President, Commercial Operations and Chief Operating Officer of Genentech from 2000 to 2005, where she also served on the Executive Committee and was Co-Chair of the Product Portfolio Committee. At Genentech Ms. Potter led the commercialization of a number of products including Avastin™, Rituxan™, Herceptin™, Tarceva™, Xolair™, Nutropin™, Activase™, and TNkase™. Prior to joining Genentech, Ms. Potter was President of Bristol-Myers Squibb’s $3.5 billion, 3,500-person U.S. Cardiovascular and Metabolic Business. Before Bristol-Myers Squibb, Ms. Potter worked at Merck & Co. for fourteen years in roles of increasing responsibility, including Vice President of an $800 million U.S. pharmaceutical business unit. While at Merck, she started the joint venture entity Astra Merck, which through merger, later became AstraZeneca. She began her career with Procter and Gamble Patient Care Products. About Myrtle Potter http://myrtlepotterconsulting.com/myrtle-potter-and-company/myrtle-potter/
Nice price jump looks like its on the way to break the size back the MA(200) at $5.54 .With positive phase 3 results in the coming weeks this low float stock will jump close or even above $10 .
It's tried this resistance level quite a few times, and now the 200MA in it's downtrend is about to add to that same resistance level, not to mention the stock is now overbought. Lots of things pointing to a bounce back down, or a pretty big breakout up to $7.00 in my opinion. If I was to take a side though, I'd probably try the short side with a fairly tight stop above the 200MA knowing there's a decent chance I'll lose, but it won't be much.
All stocks i recommend here on stockaholics are based on my own research and im a shareholder of these stocks i never got even a single penny from anyone . -------------------- Ladenburg Thalmann raised its price target on Axsome Therapeutics (NASDAQ: AXSM) to $31.00 (from $28.00) while maintaining a Buy rating. July 26, 2017 6:48 AM EDT https://www.streetinsider.com/Analy...ed+to+$31+at+Ladenburg+Thalmann/13129605.html Analyst Matt Kaplan comments "Interim Phase 3 data for CRPS is expected in 4Q17, with AXS-02 potentially being initially launched in the US in 2019, and other indications following in later years. We estimate AXS-02 can achieve $150 million in revenue in CRPS, with other pain indications also adding materially. At peak, we estimate AXS-02 can reach $600 million."
2 BIG P3 READOUT THIS MONTH=$$$$$ GET SOME AXSM AXSM (MC $120 M) (Cash $40 M) Shares Out 25.4 M // 7x Phase 3 programs in various indications targeting billion dollar markets ..2x Phase 3 readout expected within THIS MONTH = Could run to $20+ .Sabby Management just bought 1.4 Million shares a few days ago which is a good sign .GL Axsome Therapeutics (AXSM) Market Cap: $120 M Cash $40 M Price: $4.75 Shares Out : 25.4 M ( 16+ Million shares held alone by Management & Institutions) Presentation from mid November (see slide 36 for upcoming milestones) http://media.corporate-ir.net/media_files/IROL/25/254022/Axsome_Presentation_13 Nov 2017.pdf Anticipated Near-Term Clinical Milestones • Clinical Trial Readouts: Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (late December 2017 to early January 2018) Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (late December 2017 to early January 2018) Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1H 2018) Axsome Therapeutics Inc (AXSM) Stake Owned by Sabby Management, LLC...Dec 4th, 2017 https://www.themarketsdaily.com/201...axsm-stake-owned-by-sabby-management-llc.html
Biotech Penny Stocks to Buy for January, No. 4: Axsome Therapeutics Inc....December 21, 2017 https://moneymorning.com/2017/12/21...s-to-buy-with-huge-catalysts-in-january-2018/ Specifically, we're going to focus on Axsome's AXS-02 drug, which is in two separate phase 3 clinical trials to treat complex regional pain syndrome and knee osteoarthritis associated with bone marrow lesions. The results for these two clinical trials are expected in late December or early January.
Looks like breakout is on the way ..2x Phase 3 readout expected within days this could push this stock noth of $10 easily ...GL
Looks like the runup to phase 3 results has just begun...GL "JPMorgan Chase & Co. increased its position in Axsome Therapeutics Inc (NASDAQ:AXSM) by 1.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,459,117 shares of the company’s stock after buying an additional 23,229 shares during the period. JPMorgan Chase & Co. owned 6.18% of Axsome Therapeutics worth $8,026,000 at the end of the most recent quarter. Several other large investors have also recently bought and sold shares of the stock. Susquehanna International Group LLP purchased a new stake in shares of Axsome Therapeutics in the second quarter worth about $188,000. Goldman Sachs Group Inc. raised its position in Axsome Therapeutics by 118.7% during the second quarter. Goldman Sachs Group Inc. now owns 67,618 shares of the company’s stock valued at $372,000 after purchasing an additional 36,698 shares during the period. Finally, Sphera Funds Management LTD. raised its position in Axsome Therapeutics by 24.9% during the second quarter. Sphera Funds Management LTD. now owns 501,000 shares of the company’s stock valued at $2,756,000 after purchasing an additional 100,000 shares during the period. Institutional investors own 23.62% of the company’s stock."
AXSM could be the next 4 - 6 bagger biotechstock https://www.tradingview.com/chart/AXSM/di8zNJvb-AXSM-could-be-the-next-4-6-bagger-biotechstock/
Axsome Therapeutics (AXSM +0.3%) enters into a research collaboration with Duke University to evaluate lead candidate AXS-05 in a Phase 2 clinical trial involving smokers who are trying to quit. The planned randomized, double-blind, placebo-controlled study will be conducted at the Duke Center for Smoking Cessation. The trial should be initiated next quarter.
AXSM = Market Cap $70 Million / Cash $41 Million or untill Q4 2019 / Shares Out 25.3 Million / 6x Phase 3 Programs in different indications targeting very large Markets ....Stock is a pure gift at this price New Presentation http://media.corporate-ir.net/media_files/IROL/25/254022/Axsome_Presentation_January_2018_r.pdf
AXSM = Market Cap $70 Million / Cash $41 Million or untill Q4 2019 / Shares Out 25.3 Million / 6x Phase 3 Programs in different indications targeting very large Markets ....Stock is a pure gift at this price
